ETF Trading Report: Pharma, Consumer ETFs in Focus
Source: Eric Dutram, Zacks Investment Research  (6/11/12)
"The pharma sector experienced a boost in trading activity to start the week. Volume across the pharma space was high as investors sought exposure to perceived safe havens." More >

A Star Is Born at ASCO 2012
Source: Medical Technology Stock Newsletter  (6/8/12)
"This year's ASCO winners appear to have solid momentum that is allowing them to buck the 'sell ASCO' mantra." More >

Reap Biotech Profits from Overlooked Spaces: Alan Carr
Source: George S. Mack, The Life Sciences Report  (6/7/12)
Within the investment community, the story goes that new antibiotics can't generate big profits and central nervous system (CNS) drugs are too difficult to develop. Investors worry they could be throwing good money after bad. Senior Biotechnology Analyst Alan Carr of Needham & Company refutes these tales and believes that product differentiation provides the formula for success. In this exclusive interview with
The Life Sciences Report,
Carr shares his deep industry knowledge and renders his very best ideas in the CNS, antibiotic, antiviral and metabolic spaces. More >

New AMA Chief: No Chaos with Court's Health Ruling
Source: Associated Press, Lindsey Tanner  (6/6/12)
"The AMA has supported Obama's health overhaul, though a vocal contingent of doctor-members has urged the group to back off that stance." More >

Six Biotech Stocks Riding the Baby Boomer Wave
Source: Diane Alter, Money Morning  (6/6/12)
"While no one has discovered a cure for Alzheimer's, cancer, Parkinson's or other ailments that come along with old age, several biotech companies are racing to cure a long list of diseases and disorders. The prospects are daunting but the possibilities in the biotech field are literally endless, for patients and investors alike." More >

ASCO 2012: Finally, Progress Reported With Targeted Treatments for Lung Cancer
Source: Anette Breindl, BioWorld  (6/5/12)
"While breast cancer's pink ribbons have become a cottage industry, many of lung cancer's victims—even if they are nonsmokers—are less enthusiastic about being the face of a disease that many people view as self-inflicted. But several presentations at this year's ASCO meeting suggested that scientists are beginning to make inroads into the disease, which kills more patients than breast, prostate and colorectal cancer combined." More >

Autologous Immunotherapy Updates at ASCO Further Define Antitumor Immune Responses
Source: Patricia Dimond, Genetic Engineering and Biotechnology News  (6/4/12)
"Accumulating clinical and immunologic evidence presented at this year's ASCO meeting moved autologous cancer therapeutics further toward meeting the need for less-toxic therapies." More >

Biotech Ideas That Will Change the World: Patrick Cox
Source: George S. Mack, The Life Sciences Report  (5/31/12)
For Patrick Cox, disruptive technologies drive change and harbor opportunity. Cox, editor of Breakthrough Technology Alert and Technology Profits Confidential, and a contributor to The Daily Reckoning, strives to find novel ideas in small-cap companies that are off investors' radar screens. In this exclusive interview with The Life Sciences Report, Cox reveals—in his characteristic none-too-shy style—where he believes investors can find huge returns in biotech companies that will change the world. More >

3 Biotech Stocks That Could Change the World
Source: George S. Mack, The Life Sciences Report  (5/31/12)
Every investor is in search of a breakthrough that will change the world. Patrick Cox has seen it all before, as an insider at Netscape Communications before it was acquired by AOL Inc. (NYSE: AOL) at the end of 1998, and before Microsoft Corp. (NASDAQ: MSFT) ever noticed that the world was shifting under its feet. The browser revolution began with the straightforward idea that all computer operating systems could be networked with seamless cross-platform ease. I recently interviewed Cox, now editor of Breakthrough Technology Alert and Technology Profits Confidential, for the story "Biotech Ideas That Will Change the World" in The Life Sciences Report. He sees a new revolution in progress as stem cell technologies and targeted therapies begin to change the entire paradigm of medical practice. More >

The 152-Year-Old Brain That Changed the Course of Science
Source: Michael Robinson, Money Morning  (5/29/12)
"An accident a century and a half ago has provided a major link to one of the biggest quests in all of science: getting a complete map of the human brain. Once we have that under our belts, you will see one biotech breakthrough after another after another." More >

M&A Likely to Grow with Deal Premiums and Multiples
Source: Alex Philippidis, Genetic Engineering & Biotech News  (5/28/12)
"The bad news for the IPO market should be good news for biopharma M&A this year. Big companies are increasingly willing to pay a big price for a larger presence, notably specialty pharma and diagnostics." More >

'Arise and Walk!'—A Miracle Cure in the Works
Source: Severine Kirchner, Daily Reckoning  (5/28/12)
"Stem cell therapies are on the threshold of making truly miraculous cures an everyday event." More >

ASCO Abstracts 2012
Source: Market Technology Stock Newsletter  (5/25/12)
"The ASCO abstracts came out last week and a review of the massive data dump has revealed a few nuggets." More >

Make Friends with Companion Diagnostics to Bolster Your Biotech Portfolio: Stephen Brozak
Source: George S. Mack of The Life Sciences Report  (5/24/12)
Hitting just the right target and engineering cells to perform certain tasks will unlock the deep secrets of biology and change the entire paradigm of medicine, says WBB Securities President and Managing Partner Stephen Brozak. He is not picking the ultimate winners just yet, but he is playing stem cell and personalized medicine developers as a diversified portfolio, knowing that successes will overpower the also-rans. In this exclusive interview with The Life Sciences Report, Brozak shares names from his list of finalists. More >

It's Like Having a 'Fountain of Youth' in a Bottle
Source: Michael A. Robinson, Money Morning  (5/23/12)
"Scientists have tweaked a benign virus so that it can extend the lifespan of mammals by up to 24%. And if taken at the right time, this modified virus could extend the average life expectancy for an American to roughly 98 years from the current 78.5." More >

Superior Biotechnology Leads to Superior Drugs
Source: Ray Blanco, The Daily Reckoning  (5/23/12)
"Revolutions in our understanding of the genome and proteome are opening up new pathways toward vanquishing the cancer foe." More >

Collectively, 'Rare' Disease Variants Are Pretty Common
Source: Anette Breindl, BioWorld  (5/22/12)
"The fact that variants are rare does not mean they are not useful for drug discovery. Cholesterol-lowering statins, for example, were identified because of rare variants that lead to extremely low cholesterol levels in their carriers." More >

World's First Stem-Cell Drug Approved
Source: Medical News Today  (5/21/12)
"The decision is historic as it's both the first stem-cell drug going into formal use, as well as the first treatment for graft-versus-host disease, a devastating breakdown occurring after a bone marrow transplant that kills around 80% of children affected." More >

Five Companies in the Casey Portfolio Worth Watching: Alex Daley
Source: George S. Mack, The Life Sciences Report  (5/17/12)
Biotech and medtech expose investors to rapid growth in healthcare innovation. In this exclusive interview with The Life Sciences Report, Chief Investment Strategist Alex Daley of Casey's Extraordinary Technology matches science to unmet needs to bring big ideas and big returns to investors. More >

Buyout Options Gaining a Foothold
Source: Alex Philippidis, Genetic Engineering and Biotechnology News  (5/17/12)
"Deals involving buyout rights have two features that make them attractive to smaller partners: up-front payments and a longer-term path to liquidity for their investors." More >

Biotech Stock ETFs: How to Ride the Surge in Mergers & Acquisitions
Source: Don Miller, Money Morning  (5/16/12)
"Investing in biotech stocks requires not only an understanding of the company's finances, but also knowledge of the company's potential based on its products and technologies. You can reduce some of the guesswork by using exchange-traded funds, which give you exposure without betting the farm on a single company." More >

Stakeholders Share Data to Design Better Trials for Neurodegenerative Diseases
Source: Patricia F. Dimond, Genetic Engineering & Biotechnology News   (5/15/12)
"The Coalition Against Major Diseases is an industrial consortia of companies willing to share precompetitive knowledge and work in support of projects identified as high priority by the FDA and in the interest of public health." More >

FDA Panel Recommends Approval of Quad Regimen
Source: Catherine Shaffer, BioWorld  (5/14/12)
"The FDA's Antiviral Drugs Advisory Committee agreed with the efficacy outcome, and there was little discussion or debate on the efficacy of Quad." More >

Venture Capital Is Not Dead. . .Just Resting!
Source: MD+DI, Brian Buntz  (5/14/12)
"Summarizing her thoughts on the venture capital model, venture capitalist Lisa Suennen jokingly quoted Monty Python's Dead Parrot sketch: 'It is not dead. . .it is just resting!'" More >

UMass to Break Ground on Biotech Testing Facility
Source: Herald News, Grant Welker  (5/13/12)
"The facility allows start-up companies to conduct research, test and scale up their products, or partner with other startups. The University of Massachusetts Dartmouth says it will eliminate a common barrier for entering the life science industry." More >